Eric J Loumeau has sold stock and made no open-market buys since Jun 2017

Eric J. Loumeau, J.D., age 61, is the Chief Legal Officer (CLO) at AnaptysBio, Inc. (NASDAQ: ANAB), a clinical-stage biotechnology company developing novel antibody therapeutics, a role he has held since May 2023.( He previously served at AnaptysBio as Chief Operating Officer and General Counsel (July 2020–May 2023), Interim Chief Financial Officer (September 2019–July 2020), and General Counsel (August 2018–May 2023), providing continuity in legal, operations, and finance leadership.(

Loumeau brings over 20 years of biotech experience, with expertise in corporate finance—including raising over $5 billion across more than 75 securities offerings—and mergers & acquisitions.( His prior roles include General Counsel & Chief Compliance Officer at Otonomy, Inc. (2015–2018), CFO and VP of Legal Affairs at Rempex Pharmaceuticals (2011–2015, through its acquisition by The Medicines Company), and General Counsel at Hollis-Eden Pharmaceuticals.( He earned a J.D. from UC Berkeley Boalt Hall School of Law and a B.S. in Finance from Brigham Young University, and served as outside counsel at firms like Skadden Arps, Cooley LLP, and others.( Recently, as a corporate insider, he sold shares in ANAB on January 5–7, 2026, amid vesting of restricted stock units.(

Written by Perplexity from public sources.